Your browser doesn't support javascript.
Aptamers targeting SARS-COV-2: a promising tool to fight against COVID-19.
Zhang, Yang; Juhas, Mario; Kwok, Chun Kit.
  • Zhang Y; College of Science, Harbin Institute of Technology (Shenzhen), Shenzhen, Guangdong, 518055, China. Electronic address: zhangyang07@hit.edu.cn.
  • Juhas M; Medical and Molecular Microbiology Unit, Department of Medicine, Faculty of Science and Medicine, University of Fribourg, Fribourg, Switzerland.
  • Kwok CK; Department of Chemistry and State Key Laboratory of Marine Pollution, Kowloon Tong, Hong Kong, SAR, China; Shenzhen Research Institute, City University of Hong Kong, Shenzhen, China.
Trends Biotechnol ; 2022 Aug 01.
Article in English | MEDLINE | ID: covidwho-2288691
ABSTRACT
SARS-CoV-2, the causative agent of COVID-19, remains among the main causes of global mortality. Although antigen/antibody-based immunoassays and neutralizing antibodies targeting SARS-CoV-2 have been successfully developed over the past 2 years, they are often inefficient and unreliable for emerging SARS-CoV-2 variants. Novel approaches against SARS-CoV-2 and its variants are therefore urgently needed. Aptamers have been developed for the detection and inhibition of several different viruses such as HIV, influenza viruses, Middle East respiratory syndrome coronavirus (MERS-CoV), and SARS-CoV. Aptamers targeting SARS-CoV-2 represent a promising tool in the fight against COVID-19, which is of paramount importance for the current and any future pandemics. This review presents recent advances and future trends in the development of aptamer-based approaches for SARS-CoV-2 diagnosis and treatment.
Keywords

Full text: Available Collection: International databases Database: MEDLINE Topics: Variants Language: English Year: 2022 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Topics: Variants Language: English Year: 2022 Document Type: Article